360Dx

Fulgent Genetics Q4 Revenues Slide 27 Percent

Feb 28, 2018

NEW YORK (GenomeWeb) – Fulgent Genetics reported after the close of the market on Wednesday a 27 percent drop in revenues year over year for the fourth quarter.

For the three months ended Dec. 31, 2017, the Temple City, California-based genetic testing firm posted $4.3 million in revenues, down from $5.9 million in Q4 2016.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Fulgent Genetics Q4 Revenues Slide 27 Percent

To read the full story....

Breaking News

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

German Stores to Begin Selling COVID-19 Rapid Antigen Tests for Home Use

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

DermTech Q4 Revenues Up 31 Percent

In Brief This Week: Abbott Laboratories, LexaGene, Caris Life Sciences, SQI Diagnostics, and More

Featured White Papers

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

What's Popular?

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

Fulgent Genetics Q4 Revenues Skyrocket

T2 Biosystems Q4 Revenues Jump 152 Percent on Strong Product Sales

Sponsorships